RecruitingNCT07513948

Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

Studying Congenital thrombotic thrombocytopenic purpura

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Enrollment: 40 target
Eligibility: 18-99 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07513948 on ClinicalTrials.gov

Other trials for Congenital thrombotic thrombocytopenic purpura

Additional recruiting or active studies for the same condition.

RECRUITINGNCT06441578
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Takeda
RECRUITINGNCT01257269
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Insel Gruppe AG, University Hospital Bern

See all trials for Congenital thrombotic thrombocytopenic purpura →

← Back to all trials